Last day of trading in BTA in NeoDynamics AB (publ) ("NeoDynamics" or the “Company") was on April 22, 2022, and stop day is today, April 26, 2022.
Through the rights issue of shares (the “Rights Issue”), NeoDynamics raises approx. SEK 69 million before deduction of issue related costs.
The Rights Issue has now been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and last day of trading in NeoDynamics´ BTA was on April 22, 2022. Stop day is April 26, 2022. Shares are estimated to be delivered on the shareholders´ account on April 28, 2022.
Redeye Aktiebolag acted as financial adviser and Advokatfirman Lindahl KB acted as legal adviser in connection with the Rights Issue. Nordic Issuing acted as the issuing agent in the Rights Issue.
For further information, please contact:
CEO Anna Eriksrud, phone +46708 444 966 or e-mail email@example.com
CFO Aaron Wong, phone +46 73 597 2011 or e-mail firstname.lastname@example.org
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in breast and axilla in over 500 patients.
NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. It consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumour whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.
This disclosure contains information that NeoDynamics is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 26-04-2022 16:17 CET.